Grants and Contributions:
Title:
ARP - Formulation of a therapeutic vector against tumors
Agreement Number:
963215
Agreement Value:
$34,690.00
Agreement Date:
Jan 4, 2021 - Mar 31, 2021
Description:
Improvement of a silica-based therapeutic vector to increase the retention of the active within the nanovector and prevent premature release during all stages of manufacturing.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Quebec, Quebec, CA G1P 4S6
Reference Number:
172-2020-2021-Q4-963215
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
743257313
Recipient Type:
For-profit organization
Recipient's Operating Name:
Pharma in silica
Recipient's Legal Name:
Pharma In Silica inc.
Federal Riding Name:
Québec
Federal Riding Number:
24059
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410